The power of R&D collaborations to improve outcomes in rare ...

Far more common than initially thought, rare disease treatments remain far too scarce.

Novartis expands in radio-oncology again with $1.3bn Artios ...

In its second licensing deal in the radio-oncology area in consecutive weeks, Novartis has agreed a $1.3 billion-plus alliance with UK biotech Artios Pharma to develop precision medicines f

COSMIC database matches drugs to cancer mutations

The world's largest database of cancer mutations can now be used to link mutations with drug treatments in what promises to be a step forward in precision oncology. 

In the precision medicine era, the line between products and...

The three biggest challenges in lung cancer, and how researc...

Despite new paradigm-shifting treatments, lung cancer remains a deadly disease – and improving outcomes requires more than just drug research.

Q&A: Medidata’s Christian Hebenstreit on clinical trials tre...

We spoke to Christian Hebenstreit, senior VP and general manager, EMEA at Medidata, a Dassault Systèmes company, to get his views on what 2020 might hold for pharma in digital, clinical